These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32426050)

  • 1. Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody-drug conjugates as lead drug candidates for clinical trials.
    Yao HP; Suthe SR; Tong XM; Wang MH
    Ther Adv Med Oncol; 2020; 12():1758835920920069. PubMed ID: 32426050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-drug conjugates targeting RON receptor tyrosine kinase as a novel strategy for treatment of triple-negative breast cancer.
    Yao HP; Suthe SR; Hudson R; Wang MH
    Drug Discov Today; 2020 Jul; 25(7):1160-1173. PubMed ID: 32479905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy.
    Yao HP; Tong XM; Hudson R; Wang MH
    J Exp Clin Cancer Res; 2020 Sep; 39(1):198. PubMed ID: 32962738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy.
    Tong XM; Feng L; Suthe SR; Weng TH; Hu CY; Liu YZ; Wu ZG; Wang MH; Yao HP
    J Immunother Cancer; 2019 Sep; 7(1):250. PubMed ID: 31519211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
    Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
    J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase.
    Koh XY; Koh XH; Hwang LA; Ferrer FJ; Rahmat SAB; Lama D; Lane DP
    Oncogene; 2019 Nov; 38(48):7342-7356. PubMed ID: 31417186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy.
    Yao HP; Hudson R; Wang MH
    Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188360. PubMed ID: 32234337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.
    Zarei O; Benvenuti S; Ustun-Alkan F; Hamzeh-Mivehroud M; Dastmalchi S
    J Cancer Res Clin Oncol; 2016 Dec; 142(12):2429-2446. PubMed ID: 27503093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Recepteur D'origine Nantais on Gastric Cancer Development and Progression.
    Yang SY; Nguyen TT; Ung TT; Jung YD
    Chonnam Med J; 2017 Sep; 53(3):178-186. PubMed ID: 29026705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
    Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
    J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recepteur d'origine nantais contributes to the development of endometriosis via promoting epithelial-mesenchymal transition of a endometrial epithelial cells.
    Yu Q; Wang J; Li T; Guo X; Ding S; Che X; Zhu L; Peng Y; Xu X; Zou G; Zhang X
    J Cell Mol Med; 2021 Feb; 25(3):1601-1612. PubMed ID: 33410267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for the binding specificity of human Recepteur d'Origine Nantais (RON) receptor tyrosine kinase to macrophage-stimulating protein.
    Chao KL; Gorlatova NV; Eisenstein E; Herzberg O
    J Biol Chem; 2014 Oct; 289(43):29948-60. PubMed ID: 25193665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
    Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
    Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells.
    Thangasamy A; Rogge J; Ammanamanchi S
    J Biol Chem; 2009 May; 284(21):14001-10. PubMed ID: 19307182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-375 Functions as a Tumor-Suppressor Gene in Gastric Cancer by Targeting Recepteur d'Origine Nantais.
    Lian S; Park JS; Xia Y; Nguyen TT; Joo YE; Kim KK; Kim HK; Jung YD
    Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27689991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.
    Hu CY; Xu XM; Hong B; Wu ZG; Qian Y; Weng TH; Liu YZ; Tang TM; Wang MH; Yao HP
    Front Oncol; 2019; 9():1377. PubMed ID: 31867280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
    Yao HP; Feng L; Weng TH; Hu CY; Suthe SR; Mostofa AGM; Chen LH; Wu ZG; Wang WL; Wang MH
    Mol Pharm; 2018 Aug; 15(8):3260-3271. PubMed ID: 29944378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase. Recepteur d'origine nantais.
    Chen YQ; Zhou YQ; Fu LH; Wang D; Wang MH
    Carcinogenesis; 2002 Nov; 23(11):1811-9. PubMed ID: 12419829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase.
    Wang MH; Wang D; Chen YQ
    Carcinogenesis; 2003 Aug; 24(8):1291-300. PubMed ID: 12807733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RON in hepatobiliary and pancreatic cancers: Pathogenesis and potential therapeutic targets.
    Chen SL; Wang GP; Shi DR; Yao SH; Chen KD; Yao HP
    World J Gastroenterol; 2021 May; 27(20):2507-2520. PubMed ID: 34092972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.